Compositions and methods are provided for evaluating the progress of disease induced by infection with Chlamydia spp. Specifically, the invention provides a mouse lung disease model of infection with Chlamydia spp. bacteria. The compositions and methods of the invention find use in evaluating the efficacy of vaccines and other therapeutic or prophylactic treatments of Chlamydia-induced disease.